

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 11, 2020

**Altimune, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-32587**  
(Commission  
File Number)

**20-2726770**  
(I.R.S. Employer  
Identification No.)

**910 Clopper Road Suite 201S**  
**Gaithersburg, Maryland**  
(Address of principal executive offices)

**20878**  
(Zip Code)

Registrant's telephone number, including area code: (240) 654-1450

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                        | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|--|----------------------|--|
| Common stock, par value \$0.0001 per share | ALT                  | The NASDAQ Global Market                     |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 11, 2020, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Diane Jorkasky, M.D. as a director of the Company’s Board, effective May 11, 2020.

Dr. Jorkasky (68) has served on the board of directors of Alzheon, Inc., a private biopharmaceutical company, since December 2019 and also served on the board of directors of Q Therapeutics, Inc. from September 2013 until August 2016. From June 2014 to August 2019, she served as Executive Vice President, Chief Medical Officer and Head of Development at Complexa Inc., a clinical stated biopharmaceutical company. Dr. Jorkasky received her MD in 1977 from the University of Pennsylvania School of Medicine and is board certified in internal medicine, nephrology and clinical pharmacology. She is a member of the Connecticut Academy of Science and Technology. Dr. Jorkasky is on the faculties of University of California, San Francisco, and Uniformed Service of Health Sciences Medical Schools, with previous faculty appointments at Yale University and the University of Pennsylvania Schools of Medicine. The Company’s Board believes that Dr. Jorkasky’s extensive experience in the biopharmaceutical industry and as a physician make her well qualified to serve as a member of the Board.

Dr. Jorkasky will be compensated for her service as a non-employee director pursuant to the Company’s Non-Employee Director Compensation Policy and received an initial option award to purchase 40,000 shares of the Company’s common stock pursuant to the Company’s 2017 Omnibus Incentive Plan. As a non-employee director, Dr. Jorkasky is also entitled to receive an annual cash retainer of \$40,000 as a member of the Board.

The Company also entered into an indemnification agreement with Dr. Jorkasky in connection with her appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company. There are no other arrangements or understandings between Dr. Jorkasky and any other persons pursuant to which she was selected as a director, and Dr. Jorkasky has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

A copy of the Company’s press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <u>Exhibit No.</u> | <u>Description</u>  |
|--------------------|---|
| 99.1               | <a href="#">Press release of Altimmune, Inc. dated May 12, 2020</a> |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2020

**ALTIMMUNE, INC.**

By: /s/ William Brown  
William Brown  
Chief Financial Officer



### **Altimune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors**

**GAITHERSBURG, Maryland, May 12, 2020** — Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. With Dr. Jorkasky's appointment, the size of the board increased to eight members.

"We are excited to welcome Diane to the Board of Directors. Her deep development experience across multiple therapeutic areas will be a tremendous asset to Altimune", said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "We look forward to Diane's contributions to the Board as we continue the important work of developing our liver disease and vaccine programs."

Dr. Jorkasky added, "After careful consideration, I am pleased to join Altimune's Board of Directors. Altimune is poised to have a significant impact on public health, and I look forward to working with my fellow Board Members."

#### **About Dr. Jorkasky**

Diane K. Jorkasky, M.D. FACP is a highly regarded pharmaceutical industry executive with a broad background across research and all phases of clinical development in multiple therapeutic areas. In addition to being a member of Altimune's Board, Dr. Jorkasky also serves as a Director on the Board of Alzheon, Inc. Prior to her current roles, she was Chief Medical Officer and Head of Development of Complexa Inc., Chief Medical Officer of Endo Pharmaceuticals, and Chief Development and Medical Officer of Aileron Therapeutics, Inc. Her experience also includes executive positions with Pfizer as its Vice President of Global Clinical Research Operations, where she was responsible for all exploratory development, clinical pharmacology and translational medicine. Of her many accomplishments, she led Pfizer's international Clinical Research Units which received certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry or academia to achieve such a recognition. Previously, Dr. Jorkasky was Vice President of Clinical Research at SmithKline Beecham, and Chief of Nephrology at Presbyterian-Penn Medical Center in Philadelphia.

Dr. Jorkasky is a member of the Connecticut Academy of Science and Technology and has been recognized by the Connecticut Women's Hall of Fame for her scientific leadership and mentoring of young women, as well as the Connecticut Council on Technology for her work in driving technological improvements in clinical research operations.



Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology, having received her medical degree from University of Pennsylvania. She is a Woodrow Wilson Visiting Fellow, on the faculties of University of California, San Francisco and Uniformed Service of Health Sciences Medical Schools, with previous faculty appointments at Yale University and the University of Pennsylvania Schools of Medicine.

#### **About Altimune**

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVID™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

#### **Contacts:**

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
[wbrown@altimmune.com](mailto:wbrown@altimmune.com)

Ashley R. Robinson  
LifeSci Advisors, LLC  
617-430-7577  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)